Erlotinib (Tarceva) is a small-molecule, orally dosed, anti-cancer drug that inhibits the
epidermal growth factor receptor. Randomized, controlled clinical studies have …

Erlotinib HCI (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available,
quinazoline-based agent that competes with adenosine triphosphate for binding with the …

Erlotinib is an orally available, reversible tyrosine kinase inhibitor of the epidermal growth
factor receptor. Encouraging activity as a single agent and in combination with other …

The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase (TK)
receptor that is frequently expressed in many epithelial tumors. The signaling pathways of …

Importance of the field: Erlotinib, a potent inhibitor of EGFR activity, is approved as a
monotherapy for the treatment of advanced NSCLC and in combination with gemcitabine for …

Importance of the field: The epidermal growth factor receptor (EGFR) is a cell surface
receptor for EGF and transforming growth factor-alpha which is overexpressed by a number …

Non-small-cell lung cancer (NSCLC) and pancreatic cancer represent two major causes of
cancer-related morbidity and mortality worldwide. Conventional cytotoxic agents seem to …

Erlotinib (Tarceva) is a human epidermal growth factor receptor type 1/epidermal growth
factor receptor (HER1/EGFR) tyrosine kinase inhibitor initially approved by the US Food and …

Epidermal growth factor receptor (EGFR) is overexpressed by several solid tumors,
including pancreatic cancer, and has become an important target for novel anticancer …

BACKGROUND:: Erlotinib is an oral tyrosine kinase inhibitor, 1026 targeting the human
epidermal receptor type 1/epidermal growth factor receptor, recently approved by the US …